Press Room


    Press Release - May 03, 2007

    Sernova Directors and Management Established for 2007/2008 -- Dr. George Adams Named Chair; Justin Leushner Becomes CEO

    Sernova Corp. (TSX-V: SVA) is pleased to announce that Sernova Director Dr. George Adams has been appointed Chair of the Board of Directors, effective immediately. Dr. Adams, who is also CEO and a director of Amorfix Life Sciences Ltd. (TSX-V: AMF), replaces long time Chairman Dr. William Cochrane, who asked to step down from the position. Dr. Cochrane will continue to serve as a director and member of board committees.

    The Company wishes to thank Dr. Cochrane for his steady and experienced guidance during his 6 year tenure as Chairman of the Board, and expresses its appreciation that Sernova will continue to benefit from his wealth of wisdom and knowledge.

    At the same meeting Devinder Randhawa, Chairman and CEO of Strathmore Mineral Corp. (TSX-V: STM) and Pacific Asia China Energy Inc. (TSX-V: PCE) was appointed as Vice-Chair and Justin Leushner assumed the position of President and CEO. Patrick Groening will remain as Corporate Secretary and CFO, and Phil Morehouse as Executive Vice-President.

    On April 19, 2007 the company held its annual general meeting and elected 6 directors to the Board: Dr. George Adams, Charles Allard, Dr. William Cochrane, Justin Leushner, Devinder Randhawa and Dr. Eldon Smith.

    About George Adams

    Currently CEO and director of Amorfix Life Sciences, Dr. Adams has an extensive history of combining science and entrepreneurial ventures. In the late 1980's he left his position as a Senior Scientist with The Canadian Red Cross Blood Transfusion Service to found the University of Ottawa's Artificial Heart Development Program which is now World Heart. In the early 1990's, he started his own company Hemo-Stat in alliance with DuPont Canada to develop diagnostic products. In 1994 he became the controlling shareholder and President of Corvita Canada and financed its research program until the company was purchased by Pfizer in 1996 and later re-sold to Boston Scientific in 1998.

    He has also previously served as CEO of the University of Toronto Innovations Foundation where he founded and obtain financing for several companies based upon breakthrough discoveries. He obtained his Ph.D. in Medical Sciences from McMaster University after completing his B.A.Sc. and M.A.Sc. in Mechanical Engineering at the University of Waterloo.

    About Devinder Randhawa Mr. Randhawa founded and is currently the President of RD Capital Inc., a privately held consulting firm providing venture capital and corporate finance services to emerging companies in Canada and the US. Mr. Randhawa also founded Strathmore Minerals Corp. in 1996 and Pacific Asia China Energy Inc. in 2005 and is currently Chairman and CEO of both companies. Mr. Randhawa was formerly the President of Lariat Capital Inc. which merged with Medicure Inc. in November 1999, and was the founder and former President and CEO of Royal County Minerals Corp. which was acquired by Canadian Gold Hunter in 2003. He received his Masters in Business Administration from the University of British Columbia in 1985.

    About Justin Leushner Mr. Leushner has had an extensive and diverse business career in the life sciences and biotechnology industries. In addition to developing a clinical islet transplant program for the London Health Sciences Centre, he co- founded Sertonex Inc. with Dr. David White, now Sernova's primary researcher on the diabetes project. Mr. Leushner was also responsible for developing a national molecular diagnostics program for MDS Inc., Canada's largest life science's company, and served as a business analyst and portfolio advisor to the Canadian Medical Discoveries Fund. An MBA graduate of the University of Western Ontario's Ivey School of Business, Mr. Leushner also holds a B.Sc. in Cell Physiology/Genetics from the University of British Columbia and numerous technical designations in Forensic Science and Molecular Biology.

    About Sernova Sernova Corp. is a Canadian based, health sciences company focused on commercializing medical technologies and currently working to cure insulin dependent diabetes using its patented Sertolin technology. According to the American Diabetes Association approximately 9 million Americans require insulin injections and it is the sixth leading cause of death in the United States. Over $100 billion per year is spent in the US on treating diabetes and its complications, and worldwide expenditures on insulin is estimated to be $25 billion annually.

    This news release may contain forward-looking statements. Forward-looking statements address future events and conditions and therefore involve inherent risks and uncertainties. Actual results may differ materially from those currently anticipated in such statements.


    "Justin Leushner"

    Justin Leushner, President and CEO

    For further information contact:

    TEL: (888) 318-7062 FAX: (250) 868-8493

    Phil Morehouse Sernova Corp.



    Press Releases from:

    2018 2017 2016 2015 2014 2013 2012

    2011 2010 2009 2008 2007 2006 2005

    2004 2003 2002 2001 2000 1999

    Featured News

    2014, January 22

    Sernova’s Disruptive Regenerative Medicine Technologies Set to Improve the Treatment of Chronic Diseases While Reducing Healthcare Costs


    2012, July 11

    Sernova Corp. developing a tiered approach to the treatment of diabetes

    Publisher: Canadian Investor Magazine
    Author: Rochelle Emnance


    2012, July 30

    Feds back local diabetes discovery

    Publisher: London Free Press
    Author: Norman De Bono

    2012, July 30

    Federal program pumps $3 million into new, London business

    Publisher: The London Free Press

    Author: Norman De Bono

    2010 July 10

    Canada's economic action plan supports business innovators

    Publisher: Federal Economic Development Agency for Southern Ontario


    2007, February 20

    "Transplanted cells may protect against diabetes without forced drug use: An interview with Dr. David White"

    Author: Julie Ickes and James Finch

    2006, October 04

    "Sertoli Cells: Mother nature's anti-rejection drug"

    Author: James Finch

    2006, August 24

    "Mass marketing diabetes reversal; novel xeno-transplants may offer new hope for type 1 diabetics"

    Author: James Finch

    Presentation and Video

    May 03, 2018

    Corporate Presentation

    April 2018

    March 29, 2018

    2018 Financial Report - 1st Quarter

    March 29, 2018

    2018 Management Discussion & Analysis (MD&A) - 1st Quarter

    December 11, 2017

    Clearance by FDA of Sernova's US IND

    Conference call audio recording

    September 11, 2017

    Sernova Fact Sheet

    Subscribe to Sernova News